Biomea Fusion, Inc. (BMEA)
| Market Cap | 147.14M +28.8% |
| Revenue (ttm) | n/a |
| Net Income | -32.54M |
| EPS | -0.47 |
| Shares Out | 72.48M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,291,010 |
| Open | 1.900 |
| Previous Close | 1.910 |
| Day's Range | 1.885 - 2.050 |
| 52-Week Range | 0.872 - 2.990 |
| Beta | -0.24 |
| Analysts | Buy |
| Price Target | 6.50 (+220.2%) |
| Earnings Date | Aug 5, 2026 |
About BMEA
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for BMEA stock is "Buy." The 12-month stock price target is $6.5, which is an increase of 220.20% from the latest price.
News
Biomea Fusion to Participate in Upcoming Investor Conferences
SAN CARLOS, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Company” or “Company management”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announce...
Biomea Fusion completes enrollment in COVALENT-211 trial
Biomea Fusion (BMEA) announced the completion of enrollment in COVALENT-211, a randomized, double-blinded, placebo-controlled Phase II clinical trial evaluating icovamenib in patients with insulin-def...
Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes
SAN CARLOS, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today an...
Citi sees up to 410% upside in 2 biotech stocks: is the risk worth it?
Citi analyst Yigal Nochomovitz sees enormous upside in two biotech stocks, but those forecasts reveal as much about risk as potential reward. Nochomovitz has a $7 target on Biomea Fusion, implying abo...
Biomea Fusion doses first patient in OPAL study
Biomea Fusion (BMEA) announced that the first participant has been dosed in a new arm of the ongoing platform research study, Investigating and Optimizing Physical Function with Weight Loss: A…
Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity
• Initiated Study to Assess the Potential Impact of the Combination of Icovamenib and Low-Dose Semaglutide on Physical Function, Body Weight, Body Composition, Muscle Health, and Metabolic Outcomes
Citi adds ‘upside 90-day catalyst watch’ on Biomea into GLP-1 data
Citi analyst Yigal Nochomovitz added an “upside 90-day catalyst watch” on Biomea Fusion (BMEA) while keeping a Buy rating on the shares with a $7 price target The firm expects…
Biomea Fusion price target lowered to $7 from $9 at Citizens
Citizens lowered the firm’s price target on Biomea Fusion (BMEA) to $7 from $9 and keeps an Outperform rating on the shares. The firm noted that data from the Phase…
Biomea Fusion reports Q2 EPS (12c), consensus (23c)
“The second quarter marked continued execution across our diabetes and obesity programs. We are near completion of enrollment in our COVALENT-211 Phase II clinical trial, continue to advance enrollmen...
Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights
SAN CARLOS, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today reported i...
Biomea Fusion Slides: Corporate presentation
Biomea Fusion has posted slides in relation to its latest quarterly earnings report, which was published on August 5, 2026.
Biomea Fusion Quarterly report: Q2 2026
Biomea Fusion has published its Q2 2026 quarterly earnings report on August 5, 2026.
Biomea Fusion Earnings release: Q2 2026
Biomea Fusion released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Biomea Fusion Slides: Corporate presentation
Biomea Fusion has posted slides in relation to its latest quarterly earnings report, which was published on July 1, 2026.
Biomea Fusion Transcript: AGM 2026
The meeting confirmed a quorum, approved the election of two Class II Directors, and ratified Deloitte & Touche LLP as independent auditors for 2026. All proposals passed by majority vote, with results to be filed with the SEC.
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study
•Translational data presented at ADA demonstrate icovamenib's potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including ...
Biomea Fusion management to meet with Citizens
Citizens Happy Hour with Management.in New Orleans on June 6 hosted by Citizens.
Biomea Fusion Transcript: Jefferies Global Healthcare Conference 2026
The company is advancing novel therapies for diabetes and obesity, focusing on menin inhibition and oral GLP-1 programs. Phase II studies target insulin-deficient and GLP-1-treated populations, with key data readouts expected in the next year.
Biomea Fusion partners with University of Leicester on obesity study
Biomea Fusion (BMEA) announced a research collaboration with the University of Leicester to evaluate its investigational menin inhibitor, icovamenib, in combination with semaglutide in obesity within ...
Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity
Collaboration will Assess the Potential Impact of the Combination of Icovamenib and Semaglutide on Physical Function, Body Weight, Body Composition, Muscle Health and Metabolic Outcomes Late-Breaking ...
Biomea Fusion Slides: Corporate presentation
Biomea Fusion has posted slides in relation to its latest quarterly earnings report, which was published on May 29, 2026.
Biomea Fusion Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
The conference highlighted a root-cause approach to diabetes by restoring beta cell function, with icovamenib showing promising results in both type 1 and type 2 diabetes. BMF-650 aims to improve oral GLP-1 therapy for obesity, with key clinical milestones expected by year-end.
Biomea Fusion to Participate at Upcoming Investor Conferences
SAN CARLOS, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that management wi...
Biomea Fusion reports Q1 EPS (17c), consensus (19c)
As of March 31, the company had cash, cash equivalents and restricted cash of $45.1M vs. $56.2M at previous quarter end. “Across our portfolio, we continue to execute with focus…
Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights
SAN CARLOS, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today reported it...